A phase 3 trial to compare efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of patients with metastatic renal cell carcinoma.

被引：5
|
作者：
Motzer, Robert J.
Grunwald, Viktor
Hutson, Thomas E.
Porta, Camillo
Powles, Thomas
Eto, Masatoshi
Dutcus, Corina E.
Baig, Mahadi Ali
Dutta, Lea
Li, Di
Choueiri, Toni K.
机构：
[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[2] Hannover Med Sch, Niedersachsen, Germany
[3] Baylor Univ, Med Ctr, Dallas, TX USA
[4] IRCCS San Matteo Univ Hosp Fdn, Pavia, Italy
[5] Barts Hlth NHS Trust St Bartholomews Hosp, London, England
[6] Kyushu Univ, Fukuoka, Japan
[7] Eisai Inc, Woodcliff Lake, NJ USA
[8] Harvard Med Sch, Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 06期
关键词：
D O I：
10.1200/JCO.2018.36.6_suppl.TPS706
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS706
引用
收藏
页数：1
相关论文
共 50 条
  • [11] Phase I study of dalteparin in combination with sunitinib as first-line treatment in patients with metastatic renal cell carcinoma
    Pill, Roberto
    Pal, Sumanta Kumar
    George, Saby
    Voortman, Jens
    Danchalvijitr, Pongwut
    Adelalye, Remi
    Webb, Nancy
    Poslinski, Diane
    Groman, Adrienne
    Hutson, Alan
    Verheul, Honk M. W.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [12] Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma
    Hsieh, James J.
    Chen, David
    Wang, Patricia I.
    Marker, Mahtab
    Redzematovic, Almedina
    Chen, Ying-Bei
    Selcuklu, S. Duygu
    Weinhold, Nils
    Bouvier, Nancy
    Huberman, Kety H.
    Bhanot, Umesh
    Chevinsky, Michael S.
    Patel, Parul
    Pinciroli, Patrizia
    Won, Helen H.
    You, Daoqi
    Viale, Agnes
    Lee, William
    Hakimi, A. Ari
    Berger, Michael F.
    Socci, Nicholas D.
    Cheng, Emily H.
    Knox, Jennifer
    Voss, Martin H.
    Voi, Maurizio
    Motzer, Robert J.
    EUROPEAN UROLOGY, 2017, 71 (03) : 405 - 414
  • [13] Randomized phase II study of sunitinib+CXCR4 inhibitor LY2510924 versus sunitinib alone in first-line treatment of patients with metastatic renal cell carcinoma.
    Hainsworth, John D.
    Mace, Joseph Ronald
    Reeves, James Andrew
    Crane, Edward J.
    Hamid, Oday
    Stille, John R.
    Flynt, Amy
    Polzer, John
    Milner, Alvin
    Roberson, Stephanie
    Arrowsmith, Edward
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [14] PHASE 3 STUDY OF PEMBROLIZUMAB plus BELZUTIFAN plus LENVATINIB OR PEMBROLIZUMAB/QUAVONLIMAB plus LENVATINIB VERSUS PEMBROLIZUMAB plus LENVATINIB AS FIRST-LINE TREATMENT FOR ADVANCED RENAL CELL CARCINOMA
    Choueiri, Toni
    Plimack, Elizabeth
    Powles, Thomas
    Voss, Martin
    Gurney, Howard
    Silverman, Rachel
    Perini, Rodolfo
    Rodriguez-Lopez, Karla
    Rini, Brian
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A447 - A447
  • [15] Anlotinib Versus Sunitinib as First-Line Treatment for Metastatic Renal Cell Carcinoma: A Randomized Phase II Clinical Trial
    Zhou, Ai-Ping
    Bai, Yuxian
    Song, Yan
    Luo, Hong
    Ren, Xiu-Bao
    Wang, Xiuwen
    Shi, Benkang
    Fu, Cheng
    Cheng, Ying
    Liu, Jiyan
    Qin, Shukui
    Li, Jun
    Li, Hanzhong
    Bai, Xianzhong
    Ye, Dingwei
    Wang, Jinwan
    Ma, Jianhui
    ONCOLOGIST, 2019, 24 (08): : E702 - E708
  • [16] Risk of treatment failure after first-line sunitinib therapy in patients with metastatic renal cell carcinoma.
    Chen, Chi-Chang
    Hess, Gregory P.
    Liu, Zhimei
    Gesme, Dean H.
    Agarwala, Sanjiv S.
    Hill, Jerrold W.
    Guo, Min Amy
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [17] First-line everolimus followed by second-line sunitinib versus the opposite treatment sequence in patients with metastatic renal cell carcinoma (mRCC)
    Knox, J. J.
    Kay, A. C.
    Schiff, E.
    Hollaender, N.
    Rouyrre, N.
    Ravaud, A.
    Motzer, R. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [18] Economic Evaluation of Everolimus versus Sorafenib for the Treatment of Metastatic Renal Cell Carcinoma after Failure of First-Line Sunitinib
    Casciano, Roman
    Chulikavit, Maruit
    Di Lorenzo, Giuseppe
    Liu, Zhimei
    Baladi, Jean-Francois
    Wang, Xufang
    Robertson, Justin
    Garrison, Lou
    VALUE IN HEALTH, 2011, 14 (06) : 846 - 851
  • [19] Phase 3 study of first-line treatment with pembrolizumab plus belzutifan plus lenvatinib or pembrolizumab/quavonlimab plus lenvatinib versus pembrolizumab plus lenvatinib for advanced renal cell carcinoma (RCC).
    Choueiri, Toni K.
    Plimack, Elizabeth R.
    Powles, Thomas
    Voss, Martin H.
    Gurney, Howard
    Silverman, Rachel Kloss
    Perini, Rodolfo F.
    Rodriguez-Lopez, Karla
    Rini, Brian I.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [20] Cost-Effectiveness of Lenvatinib Plus Pembrolizumab or Everolimus as First-Line Treatment of Advanced Renal Cell Carcinoma
    Wang, Ye
    Wang, Hao
    Yi, Manman
    Han, Zhou
    Li, Li
    FRONTIERS IN ONCOLOGY, 2022, 12
12345